This article was downloaded by:

On: 26 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597286

Conformational Analysis of Nucleosides Constructed on a Bicyclo[3.1.0]hexane Template. Structure-Antiviral Activity Analysis for the Northern and Southern Hemispheres of the Pseudorotational Cycle

Victor E. Marquez<sup>a</sup>; Abdallah Ezzitouni<sup>a</sup>; Maqbool A. Siddiqui<sup>a</sup>; Pamela Russ<sup>a</sup>; Hisafumi Ikeda<sup>a</sup>; Clifford George<sup>b</sup>

<sup>a</sup> Laboratory of Medicinal Chemistry, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD <sup>b</sup> Laboratory for the Structure of Matter, Naval Research Laboratory, Washington, DC

To cite this Article Marquez, Victor E., Ezzitouni, Abdallah, Siddiqui, Maqbool A., Russ, Pamela, Ikeda, Hisafumi and George, Clifford (1997) 'Conformational Analysis of Nucleosides Constructed on a Bicyclo [3.1.0] hexane Template. Structure-Antiviral Activity Analysis for the Northern and Southern Hemispheres of the Pseudorotational Cycle', Nucleosides, Nucleotides and Nucleic Acids, 16: 7, 1431 - 1434

To link to this Article: DOI: 10.1080/07328319708006199
URL: http://dx.doi.org/10.1080/07328319708006199

## PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

# CONFORMATIONAL ANALYSIS OF NUCLEOSIDES CONSTRUCTED ON A BICYCLO[3.1.0]HEXANE TEMPLATE. STRUCTURE-ANTIVIRAL ACTIVITY ANALYSIS FOR THE NORTHERN AND SOUTHERN HEMISPHERES OF THE PSEUDOROTATIONAL CYCLE

Victor E. Marquez\*1, Abdallah Ezzitouni, Maqbool A. Siddiqui, Pamela Russ, Hisafumi Ikeda, and Clifford George2

<sup>1</sup>Laboratory of Medicinal Chemistry, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, and <sup>2</sup>Laboratory for the Structure of Matter, Naval Research Laboratory, Washington, DC 20375

**Abstract.** A conformational analysis of carbocyclic nucleosides built on a rigid bicyclo[3.1.0]hexane template (1-4, Northern and 5-8 Southern) showed that the Northern conformation prefers an *anti* glycosyl torsion angle whereas the Southern conformation favors the *syn* range. Antiviral activity was mostly associated with the Northern conformers.

#### Introduction.

The complete definition of the conformation of a nucleoside involves the determination of four structural parameters: (a) the orientation about the glycosyl bond (torsion angle  $\chi$ ) as syn or anti, (b) the orientation of the hydroxymethyl group determined by the torsion angle  $\gamma$ , (c) the puckering of the sugar ring measured by the angle of pseudorotation P, and (d) the maximum out-of-plane pucker given by  $v_{max}$ . For a conventional nucleoside, these parameters are subject to changes that are dependent on the nature of the substituents present on the base and on the sugar moiety. However, when a nucleoside is constructed

HO
$$\chi$$
B
 $\chi$ 

Figure 1

$\vdash$			
⊣			
0			
(1			
5.			
ы			
ď			
2			
Ħ			
Ь			
-			
9			
C/J			
~			
'n			
Ŋ			
$\vdash$			
1.)			
A.			
Downloaded At: 15:57 26 January 2011			
ත			
ž			
ĕ			
Õ			
ᅼ			
Н			
ń			
ŏ			

Table 1. Co	Table 1. Conformational parameters for bicyclo[3.1.0]hexane nucleosides	neters for bicyclo	[3.1.0]hexane nuc	leosides			
Compound	P ± s.d (# conformers) ΔE > Glob. Min.	v <sub>max</sub> ± s.d (# conformers)	Glob. Min. Conformation* P, &, \gamma	anti/syn	E <sub>syn/anti</sub> (Kcal/mol)	E <sub>y</sub> (Kcal/mol)	P and v <sub>max</sub> for Highest Energy conformer
1	343.35 ± 3.53 (n = 14) 5 Kcal/mol	29.95 ± 5.29 (n = 14)	344.37* anti Y <sup>+</sup>	9/8	8.0	2.8-3.5	P = 337.87 $v_{max} = 38.98$
64	344.16 ± 3.70 (n = 12) 5 Kcal/mol	29.33 ± 5.17 (n = 12)	344.23* anti Y <sup>+</sup>	9/9	7.7	2.8-3.5	$P = 338.05$ $v_{max} = 38.89$
E	342.97 ± 2.50 (n = 12) 1 Kcal/mol	$32.17 \pm 2.51$ (n = 12)	343.46 anti Y <sup>+</sup>	8/4	2.5	1.5-2.0	P = 338.89 $v_{max} = 35.69$
4	344.20 ± 2.65 (n = 12) 2 Kcal/mol	$31.42 \pm 2.75$ (n = 12)	343.45** anti Y <sup>+</sup>	9/9	2.6	1.5-2.0	P = 338.89 $v_{max} = 35.89$
ĸ	192.51 ± 4.22 (n = 9) 5 Kcal/mol	28.09 ± 1.49 (n = 9)	191.28* syn Y	4/5	9.0	4.4-4.9	P = 198.07 $V_{max} = 31.51$
9	194.51 ± 5.91 (n = 10) 5 Kcal/mol	$28.20 \pm 2.02$ (n = 10)	191.62* syn T	4/6	7.9	4.4-4.9	P = 200.17 $v_{max} = 32.10$
7	190.49 ± 1.85 (n = 9) 1 Kcal/mol	28.00 ± 0.62 (n=9)	190.65 syn Y	5/4	2.8	3.4-4.4	P = 198.07 $v_{max} = 29.20$
∞	191.65 ± 1.98 (n = 12) 2 Kcal/mol	$27.93 \pm 0.69$ (n = 12)	190.93 syn Y <sup>+</sup>	8/4	3.0	3.4-4.4	P = 197.20 $V_{max} = 31.53$
			THE COLUMN TWO TICKS IN THE COLUMN TO THE COLUMN TWO THE COLUMN TW	T. TIO III	111 (0)0 11		

(\*) Conformation without CH<sub>2</sub>OH...O=C(3) H-bond. (\*\*) Conformation without CH<sub>2</sub>OH...NH<sub>2</sub>-C(2) H-bond.

	Virus <sup>a</sup> (host cell)	EC <sub>50</sub> <sup>b</sup> (µg/ml)	CC <sub>50</sub> c (µg/ml)	SI <sup>d</sup>	Control <sup>e</sup> EC <sub>50</sub> (µg/ml)	
1	HSV-1	0.01 <sup>f</sup>	>20	>2000	0.30	
"	HSV-2	0.12 <sup>f</sup>	>20	>167	0.80	
"	HCMV	>20	63.7	<3.2	0.30	
2	HSV-1	0.14	68.0	486	0.70	
"	HSV-2	>20	96.0	<4.8	6.20	
44	HCMV	>4.0	8.8	<2.2	0.02	
3	HSV-1	72.0	>100	>1.4	0.80	
"	HSV-2	13.9	>100	>7.2	4.0	
"	HCMV	5.6 <sup>f</sup>	>100	>17.9	0.30	
7	HSV-1	>100	>100	1	0.20	
	HSV-2	>100	>100	1	0.20	
	HCMV	2.4 <sup>f</sup>	>100	>41.7	0.20	
4	HSV-1	4.0	>100	>25	0.60	
"	HSV-2	9.9	>100	>10.1	1.50	
"	HCMV	>20	64.3	<3.2	0.40	

**Table 2.** Selected antiviral activity of some 2'-deoxy-*methano-carbocyclic* nucleosides.

<sup>a</sup>HSV-1 = herpes simplex type 1; HSV-2 = herpes simplex type 2; HCMV = human cytomegalovirus.  ${}^{b}EC_{50}$  = inhibitory concentration required to reduce virus-induced cytopathogenicity or virus plaques by 50%.  ${}^{c}CC_{50}$  = cytotoxic concentration that produces 50% of cell death.  ${}^{d}SI$  = selectivity index (CC<sub>50</sub>/EC<sub>50</sub>).  ${}^{e}ACV$  = acyclovir control (for HSV-1 and HSV-2), GCV = gancyclovir control (for HCMV).  ${}^{f}These$  values correspond to a plaque reduction assay.

with a rigid pseudosugar moiety, the third and fourth parameters can be constrained to values typical of strictly Northern (N) or Southern (S) conformations (Figure 1). We were interested in studying the effect that a constrained pseudosugar moiety would have on the *syn* and *anti* orientation of the glycosyl link since it is known that this equilibrium is finely tuned by the sugar pucker.<sup>1</sup>

## Conformational Analysis

A conformational analysis of compounds 1-4 (N) and 5-8 (S) using MM2 force field parameters was performed by simultaneously changing the values of  $\chi$  and  $\gamma$ . The potential

1434 MARQUEZ ET AL.

energy maps generated revealed the effects that the rigid pseudosugar moiety had on the torsion angles  $\chi$  and  $\gamma$ , and the energy barriers for the syn/anti equilibrium without the stiff pseudosugar moiety compensating for any repulsive interactions (Table 1). If the strong intramolecular H-bond between the primary alcohol and the C-3 pyrimidine carbonyl (favored by the calculations in vacuo) is neglected, pyrimidine conformers 1 and 2 favor the anti conformation. Similarly for the guanosine analogue 4, exclusion of the H-bond between the primary alcohol and the C-2 amino group favors the anti conformation. Available crystallographic data for  $1^2$  and  $3^3$  showed that these N compounds appear anti. For the S pyrimidine conformers (5 and 6) H-bond favors the expected syn conformation. This conformation remais favored even in the absence of H-bonding. The S purines also seem to prefer the syn conformation where no H-bond contribution was evidenced. The anti/syn preference is obviously determined by the energy barrier between these conformations. This energy barrier changes little in each hemisphere and it is lower for purines than for pyrimidines (Table 1). Crystallographic analysis of 54 revealed exclusively the syn conformer, whereas in the X-ray structure of 75 the unit cell contained both syn and anti conformers, thus reflecting a much lower energy barrier. Rotation about y changed not only for each hemisphere, but it depended on the nature of the base. The trend is that hindrance to rotation of y is greater for pyrimidines, and that it also increases in the N  $\rightarrow$  S direction. In summary, the energy barriers calculated for  $\chi$  and  $\gamma$  seem to indicate that the conformational space (number of low energy conformers in Table 1) for pyrimidines is more restricted, particularly for those constrained to the S hemisphere.

## Antiviral activity.

The compounds were evaluated primarily against herpes (HSV-1 and 2) and HCMV (Table 2). Antiviral activity was mostly associated with the N conformers with the exception of the S adenosine analogue 7 which showed significant anti-HCMV activity.

## References

- 1. Saenger, W. *Principles in Nucleic Acid Structure*, Springer-Verlag, New York, 1984, pp 51-104.
- Altmann, K.-H.; Kesselring, R.; Francotte, E.; Rihs, G. Tetrahedron Lett. 1994, 35, 2331.
- Siddiqui, M. A.; Ford, Jr., H.; George, C.; Marquez, V. E. Nucleosides Nucleotides 1996, 15, 235.
- 4. Altmann, K-H.; Imwinkelried, R.; Kesselring, R.; Rihs, G. Tetrahedron Lett. 1994, 35, 7625.
- 5. Unpublished results.